NCT00492427 - Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta) | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

November 30, 2008

Conditions

Predialysis Patients

Interventions

DRUG

R744

25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.

DRUG

Epoetin beta

6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.

Trial Locations (6)

Unknown

Chugoku/Shikoku region, Chugoku/Shikoku

Chubu region, Chūbu

Hokkaido/Tohoku region, Hokkaido/Tohoku

Kanto/Koshinetsu region, Kanto/Koshinetsu

Kinki/Hokuriku region, Kinki/Hokuriku

Kyusyu region, Kyusyu